Docetaxel Plus Famitinib Versus Docetaxel Plus Placebo in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Apr 2018
At a glance
- Drugs Docetaxel (Primary) ; Famitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 16 Apr 2018 Planned End Date changed from 1 Dec 2016 to 1 Jun 2019.
- 16 Apr 2018 Planned primary completion date changed from 1 Jun 2015 to 1 Dec 2018.
- 07 Jun 2016 Status changed from recruiting to active, no longer recruiting, as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology